Cantor Fitzgerald Downgrades Intra-Cellular Therapies (ITCI) to Neutral
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Price: $131.87 --0%
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
9 Buy, 11 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Cantor Fitzgerald analyst Charles Duncan downgraded Intra-Cellular Therapies (NASDAQ: ITCI) from Overweight to Neutral with a price target of $132.00 (from $135.00).
For an analyst ratings summary and ratings history on Intra-Cellular Therapies click here. For more ratings news on Intra-Cellular Therapies click here.
Shares of Intra-Cellular Therapies closed at $94.87 yesterday.
You May Also Be Interested In
- Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
- Zedcor Inc (ZDC:CN) PT Raised to Cdn$7.75 at Desjardins
- Honasa Consumer Ltd (HONASA:IN) PT Raised to INR720 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
